INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other EventsItem 9.01 Other Events.
On August1, 2017,Innoviva,Inc. issued a press release announcing that it had priced its previously announced offering of $175.0 million of convertible senior notes due 2025. A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
|
99.1 |
Press Release dated August1, 2017. |
Innoviva, Inc. ExhibitEX-99.1 2 a17-18560_3ex99d1.htm EX-99.1 Exhibit 99.1 Innoviva,…To view the full exhibit click here
About INNOVIVA,INC. (NASDAQ:INVA)
Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).